Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Basic financial performance shows decreased R&D expenses but increased SG&A, and a significant noncash net loss. Product development updates are positive, with confidence in pivotal study results. Market strategy faces hurdles with reimbursement pathways. Financial health is stable with cash to fund operations till 2027. Shareholder returns were not discussed. The Q&A reveals positive sentiment towards ablation efficacy but management's avoidance of specifics on secondary endpoints raises concerns. Overall, the mixed financials and strategic uncertainties balance out the positive product developments, leading to a neutral sentiment.
Key Financial Performance
Research and Development Expenses $16.5 million for Q4 2025, a decrease from $20.3 million in Q4 2024. The decrease was primarily due to strategic reprioritization in Q1 2025, resulting in lower personnel-related costs and reduced costs associated with the pausing of the REVITALIZE-1 study, partially offset by continued investment in REMAIN-1 and Rejuva.
SG&A Expenses $6.8 million for Q4 2025, an increase from $4.9 million in Q4 2024. The increase was primarily due to underwriters commissions associated with the August 2025 financing.
Net Loss $43.7 million for Q4 2025, an increase from $25 million in Q4 2024. However, $20.2 million of the increase was a noncash accounting change in the fair value of warrant liabilities, which does not reflect a change in underlying operating performance.
Adjusted EBITDA Negative $21.2 million for Q4 2025, an improvement from negative $22.1 million in Q4 2024, reflecting the decrease in operating expenses.
Cash and Cash Equivalents Approximately $81.5 million as of December 31, 2025. Combined with $4.1 million subsequent proceeds from warrant exercises received in January 2026, this funds operations into early 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revita: Revita is an endoscopic procedure designed to maintain weight loss after GLP-1 discontinuation. Recent findings show a strong dose-response relationship between ablation length and weight maintenance, with longer ablations leading to better outcomes. The pivotal study is designed to optimize these findings, with a mean ablation length of over 16 cm.
Rejuva: Rejuva is a smart GLP-1 platform targeting long-term metabolic remission from a single dose. Clinical trial applications have been submitted in the EU and Australia, with regulatory feedback expected in Q2 2026.
GLP-1 Market Opportunity: The GLP-1 market is projected to grow to over 30 million users in the coming years. Revita targets the unmet need for post-GLP-1 weight maintenance, with a potential market of patients discontinuing GLP-1 therapy after significant weight loss.
Reimbursement Pathway: A clear reimbursement pathway has been established for Revita, including a Category III CPT code application expected to be effective in 2027. CMS transitional pass-through payment will support hospital economics.
Pivotal Study Progress: The REMAIN-1 pivotal study has completed randomization with over 300 participants across 30+ sites. Retention exceeds 95%, and operational metrics are tracking favorably for success.
Regulatory Feedback: The FDA has provided favorable feedback on Revita's safety profile, supporting a Class II device classification. A De Novo submission is planned for late Q4 2026.
Capital Strategy: The company has closed its ATM facility and does not plan to raise capital before pivotal data is available. Current cash reserves are expected to fund operations into early 2027.
Strategic Reprioritization: The company has strategically reprioritized its resources, reducing costs in certain areas while focusing on the REMAIN-1 and Rejuva programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Data Challenges: The 6-month Midpoint Cohort data showed weaker results compared to the 3-month data, attributed to site-level heterogeneity and differences in ablation length, which could impact the efficacy of the Revita procedure.
Operational Scalability: Ensuring consistent ablation length across diverse operators and patient anatomies is critical for achieving repeatable outcomes, posing a challenge to procedural standardization.
Regulatory Risks: Although the FDA provided favorable feedback on the De Novo classification request, the regulatory pathway remains complex and subject to potential delays or additional requirements.
Financial Sustainability: The company reported a net loss of $43.7 million for Q4 2025 and is reliant on its current cash position to fund operations into early 2027, with no plans for additional capital raises before pivotal data is available.
Market Adoption Risks: The success of Revita depends on its acceptance by commercial stakeholders and payers, particularly in a competitive and evolving GLP-1 therapy landscape.
Reimbursement Challenges: The company plans to file a Category III CPT code application, but reimbursement pathways and payer acceptance could pose hurdles to commercial success.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revita pivotal study: The pivotal study is designed to demonstrate the efficacy of Revita for post-GLP-1 weight maintenance. The study is well-powered at over 90% to achieve its co-primary endpoints, which include percent body weight regain at 6 months and the proportion of patients maintaining at least 5% total body weight loss at 1 year. Top-line 6-month data is expected in early Q4 2026, with a De Novo marketing application submission planned for late Q4 2026.
Regulatory progress: The FDA has provided favorable feedback on Revita's safety profile, consistent with a Class II device classification. This supports the planned De Novo submission in late Q4 2026.
Commercial launch preparation: The company is preparing for a potential commercial launch of Revita, targeting a large and growing population of GLP-1 users. A Category III CPT code application will be filed in summer 2027, with reimbursement pathways already validated.
Market opportunity: The addressable market for Revita is expanding, with over 30 million projected GLP-1 users in the coming years. The unmet need for post-GLP-1 weight maintenance solutions is intensifying, creating a significant commercial opportunity.
Rejuva program: The Rejuva program, targeting long-term metabolic remission from a single dose, is advancing with clinical trial applications submitted in the EU and Australia. Regulatory feedback is expected in Q2 2026, with first-in-human dosing and preliminary data anticipated in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the ablation length determined during the procedure, and is 16 centimeters the target minimum ablation length?
A:The ablation length is determined by counting the number of ablations performed longitudinally along the duodenum. The target minimum ablation length is now set at 16 centimeters, as it has shown clinically meaningful and compounding treatment effects.
Q:Does the target ablation length impact how doctors are trained, and were shorter ablations due to physician discomfort?
A:In the pivotal study, doctors were advised to ablate at least 10 centimeters, and all were trained to perform greater than 14 centimeters of ablation. The data now supports training physicians to consistently achieve 16 centimeters, which is considered the efficacious dose.
Q:To what extent does efficacy play a role in the FDA's De Novo pathway determination?
A:The De Novo pathway determination is primarily a safety consideration. The efficacy threshold for De Novo is 'reasonable assurance of safety and effectiveness,' whereas for PMA, it is 'valid scientific evidence.'
Q:Is 16 centimeters of ablation readily achievable in real-world scenarios?
A:Yes, in the Pivotal Cohort, the mean and median ablation length were greater than 16 centimeters, and it is considered readily achievable by trained investigators.
Q:Can you provide more details on the post-hoc analysis for the midpoint data set and its impact on confidence for the pivotal readout?
A:The post-hoc analysis showed that the mean and median ablation length in the Pivotal Cohort were greater than 16 centimeters, longer than in the Midpoint Cohort. This supports confidence in the pivotal study, which is well-powered and includes key secondary endpoints to demonstrate efficacy.
Q:How long does it take to train physicians to perform adequate ablations?
A:It takes less than 3 to 4 cases to train a physician to perform adequate ablations. Physicians quickly become comfortable and consistently deliver longer ablations after initial cases.
Q:Will the Q3 1-year remain Midpoint Cohort data include further analysis by ablation length?
A:Yes, further analysis by ablation length will be included in the Q3 1-year remain Midpoint Cohort data.
Q:Has anything changed in energy delivery or temperatures between the Midpoint Cohort and the Pivotal Cohort?
A:No, there have been no changes in energy delivery or temperatures. The treatment has remained consistent and standardized across sites and operators.
Q:What is the timeline for filing the CPT code and reimbursement authorization?
A:The Category III CPT code will be filed in June 2023, reviewed in September, and take effect in July 2027. A transitional pass-through payment through CMS will be filed immediately upon FDA authorization, with a quarterly review cycle allowing for quick implementation.
Q:What is the process for regulatory submissions over the next year, and how does the ablation length factor into the statistical analysis plan?
A:Regulatory submissions include a design history file, manufacturing file, and clinical data. The ablation length is a prespecified population in the pivotal study, and key secondary endpoints are designed to demonstrate efficacy clearly. Details on the statistical analysis plan hierarchy are pending FDA discussions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the hierarchy of secondary endpoints in the statistical analysis plan, stating that it is pending discussions with the FDA.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
De Novo
FDA
GLP
Midpoint Cohort
Number
Pivotal Cohort
ablation length
analysis
body weight
centimeter
co primary
device
discontinuation
dose
endpoint
feedback
human
magnitude weight
metabolic
patient
population
profile
relationship ablation
response
sham
signal
site
study ablation
therapy
treatment effect
type diabetes
weight loss
weight maintenance
GUTS Transcript
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents mixed signals. Basic financial performance shows decreased R&D expenses but increased SG&A, and a significant noncash net loss. Product development updates are positive, with confidence in pivotal study results. Market strategy faces hurdles with reimbursement pathways. Financial health is stable with cash to fund operations till 2027. Shareholder returns were not discussed. The Q&A reveals positive sentiment towards ablation efficacy but management's avoidance of specifics on secondary endpoints raises concerns. Overall, the mixed financials and strategic uncertainties balance out the positive product developments, leading to a neutral sentiment.
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a mixed but overall positive outlook. The company's strategic initiatives, including the Revita therapy and Rejuva program, show promise with significant weight loss results and ongoing clinical trials. Despite increased net loss due to non-cash accounting changes, the cash position is strong, extending into 2027. The Q&A highlighted consistent weight loss data and ongoing efforts for market preparation. However, the lack of specific guidance on RJVA-002 receptor potency could be a concern. Overall, the positive clinical data and strategic planning outweigh the negatives, suggesting a positive stock reaction.
WildBrain Ltd. (WILD:CA) Q4 2025 Earnings Call Transcript
Unknown9-26
The earnings call shows mixed signals: strong licensing growth but declining content revenue and gross margins. Positive cash flow and reduced net loss are offset by inconsistent margins and unclear guidance on AI impact. Q&A reveals optimism in digital and licensing but lacks detailed ROI. Overall, the sentiment is neutral, as positive aspects are balanced by concerns about margin decline and vague future projections.
Fractyl Health, Inc. (GUTS) REMAIN-1 Midpoint Cohort Three-Month Results Conference Call (Transcript)
Neutral9-26
GUTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
